Obesity Clinical Trial
— PKUBC-TOfficial title:
Peking University Birth Cohort in Tongzhou
Verified date | November 2023 |
Source | Peking University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The PKUBC-T is a prospective cohort study carried out in Tongzhou district of Beijing, China. The primary aim of this study is to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. Data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers and their children from birth to 6 years old. Biological samples including blood and tissue samples are also collected from mothers and their children.
Status | Active, not recruiting |
Enrollment | 5426 |
Est. completion date | August 28, 2025 |
Est. primary completion date | August 27, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: 1. Pregnant women, <14 gestational weeks 2. Resided in Tongzhou in the past half years and have no plan to move out after delivery 3. Pregnant women who plan to have antenatal care and delivery in Tongzhou maternal&Child Hospital. 4. Pregnant women who is willing to participate in this study with informed consent Exclusion Criteria: Pregnant women have chronic disease before pregnancy, including diabetes,hypertension, liver disease and kidney disease. |
Country | Name | City | State |
---|---|---|---|
China | Peking University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University | National Natural Science Foundation of China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Numbers of participants with pregnancy complications | Including gestational diabetes, gestational hypertension, anemia, and hypothyroidism during pregnancy | At delivery | |
Primary | Numbers of participants with adverse pregnancy outcomes | Including preterm birth, low birth weight, macrosomia, abortion, stillbirth, and birth defects. | At delivery | |
Secondary | Weight in kilogram changes during childhood | Measured by health professionals in clinic | At birth and age at 6 weeks, 3 months, 6 months, 8 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 4 years, 5 years and 6 years | |
Secondary | Height in centimeter changes during childhood | Measured by health professionals in clinic | At birth and age at 6 weeks, 3 months, 6 months, 8 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 4 years, 5 years and 6 years | |
Secondary | Early Child development 1 | Measured by Ages&Stages Questionnaires (ASQ).There are 6 questions in each of 5 domains of development: communication, gross motor, fine motor, problem-solving skills, and adaptive skills. Each question is given a 10 (yes), 5 (sometimes), or 0 (not yet) score according to the parents' answers. The sum scores (range from 0 to 300) and scores for each domain (range from 0 to 60) are calculated. Chinese norms are available for each domain, and any domain screened <2 SDs below the mean is considered a positive screening. A higher ASQ score means better development. | Age at 6 weeks and 3 years | |
Secondary | Early Child development 2 | Measured by Denver Developmental Screening Test (DDST). DDST comprises 125 test items grouped into four domains of child development: 25 personal-social (PS), 29 fine motor (FM), 39 language (LA) and 32 gross motor (GM). These test items are administered using a bell, glass bottle, set of 10 blocks, rattle, pencil, tennis ball, yarn, raisins, cup, white doll, white paper, and baby bottle. A child's raw score on each test item is marked as tested pass, failure, refusal, or no opportunity. The result of the test is labeled as "normal," "suspect" or "abnormal". Normal development means that there is no delay or at the maximum one warning. Abnormal development means that there is one or more than one delay situation. Suspicious development means that it is a situation involving one delay, one delay and one warning or two or more than two warnings. The number of children with normal, suspect or abnormal development is calculated. | Age at 8-12 months | |
Secondary | Incidence of diabetes mellitus in women | Measured by health professionals in clinic | 6 weeks after delivery and 3 years after delivery | |
Secondary | Incidence of hypertension in women | Measured by health professionals in clinic | 6 weeks after delivery and 3 years after delivery | |
Secondary | Incidence of child overweight and obesity | Measured by health professionals in clinic | Age at 6 weeks, 3 months, 6 months, 8 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 4 years, 5 years and 6 years | |
Secondary | The proportion of children with warning signs | Measured by warning signs screening | Age at 3 months, 6 months, 8 months, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 4 years, 5 years and 6 years | |
Secondary | Fetal Biparietal Diameter | Measured by health professionals in clinic with ultrasound | At 20-24 gestational week, 30-32 gestational week and 37-41 gestational week. | |
Secondary | Fetal Head Circumference | Measured by health professionals in clinic with ultrasound | At 20-24 gestational week, 30-32 gestational week and 37-41 gestational week. | |
Secondary | Fetal Abdominal Circumference | Measured by health professionals in clinic with ultrasound | At 20-24 gestational week, 30-32 gestational week and 37-41 gestational week. | |
Secondary | Fetal Femur Length | Measured by health professionals in clinic with ultrasound | At 20-24 gestational week, 30-32 gestational week and 37-41 gestational week. | |
Secondary | Fetal Humerus Length | Measured by health professionals in clinic with ultrasound | At 20-24 gestational week, 30-32 gestational week and 37-41 gestational week. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |